Study Phase 1

A Phase I, Partially Randomized, Open Label, Two-way, Two Period Cross-over Study to Investigate the Pharmacokinetic Interaction Between Etravirine or Darunavir/Rtv and Artemether/Lumefantrine at Steady-state in Healthy HIV-negative Subjects

Trial Information

Generic NameEtravirineProduct NameINTELENCE®Therapeutic AreaAnti-Infectives for Systemic UseProduct ClassAntivirals for Systemic UsePharmacological SubgroupDirect Acting AntiviralsChemical SubgroupNon-Nucleoside Reverse Transcriptase InhibitorsCondition StudiedHIV Infections
Sponsor Protocol NumberTMC125VIR1001Enrollment33Data PartnerJohnson & Johnson% Female0.0%Mean/Median Age (Years)27.0% White100%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.